Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Xaar reports weaker financial performance in 'mixed' year

(Sharecast News) - Xaar reported a weaker financial performance for the year ended 31 December on Tuesday, reflecting challenging end markets, particularly in ceramics and engineered systems, although the company made strategic progress in new growth areas that were expected to support stronger performance in the medium term. The London-listed company said group revenue declined 13% to £61.4m, while adjusted profit before tax fell sharply to £0.3m from £2.9m.

Adjusted EBITDA declined 42% to £3.7m and adjusted earnings per share dropped to 0.7p.

The reported loss for the year widened to £10.7m from £2.4m in 2023.

Despite the top-line pressure, Xaar maintained a gross margin of 36%, down just two percentage points, supported by proactive cost control and a 16% reduction in adjusted operating expenses.

Gross research and development investment remained steady at around 9% of revenue.

The group ended the year with a strengthened net cash position of £8.7m, up 23% year-on-year, aided by improvements in working capital.

Xaar said its printhead business was a notable bright spot, growing revenue 23% to £18.9m, driven by early progress in new applications, including EV battery coating, 3D printing, and textiles.

That helped to offset significant declines elsewhere, with revenue in ceramics and glass falling to £7.5m from £15.5m, and engineered print systems revenue down 27% to £16.1m following the completion of a major multi-year project.

Strategic developments during the year included new customer wins and partnerships.

Xaar-enabled coating lines were launched by Omijia and Shifang for the EV battery market, while an exclusive agreement with Axalta and Dürr positioned Xaar in automotive coatings.

Printheads were also integrated into a new high-resolution colour desktop 3D printer, and OEM product launches in wax and textiles validated its broadened offering.

Looking ahead, Xaar said it expected medium-term revenue growth and margin expansion as key partnerships and product launches gain traction.

In the near term, however, continued softness in end markets, particularly for engineered print systems, was likely to weigh on results.

Management remained focussed on tight cost control and preserving its cash position as it executed on its strategy and rebuilt its sales pipeline.

"2024 was a mixed year; while we did not meet our original revenue aims, we did make strong strategic progress and delivered both a profit and increased cash over the year," said chief executive officer John Mills.

"Our key strategic milestones, notably in the areas of EV battery coating, automotive coating and desktop 3D, are setting the group up for sustainable medium-term growth and are all progressing as planned.

"Increasing market awareness of our value proposition also means that global market leaders are now approaching us to learn more about the benefits of high viscosity fluids."

Mills said that additionally, the provision of a complete turnkey solution to M&R, a major player within the textiles market, had proven "extremely" successful.

"With a second project ongoing, we continue to evaluate opportunities to roll out this go-to-market strategy to additional markets and customers, potentially transforming our future rate of growth and market capture.

"With the ceramics market decline nearing its trough, this headwind should reduce going forward, allowing new business revenue growth to translate to profit more readily.

"Overall, the visibility and scale of the medium-term opportunities at Xaar continue to grow.

"Combined with the cash on our balance sheet, we remain well-positioned to generate sustainable growth."

At 0936 GMT, shares in Xaar were up 6.67% at 64p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.